BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25356925)

  • 1. Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab.
    Salmasi G; Li M; Sivabalasundaram V; Panzarella T; Tsang R; Kukreti V; Crump M; Kuruvilla J
    Leuk Lymphoma; 2015 Jun; 56(6):1659-64. PubMed ID: 25356925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
    Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.
    Katsuya H; Suzumiya J; Sasaki H; Ishitsuka K; Shibata T; Takamatsu Y; Tamura K
    Leuk Lymphoma; 2009 Nov; 50(11):1818-23. PubMed ID: 19863173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China.
    Hou S; Yang W
    Saudi Med J; 2011 Jul; 32(7):675-8. PubMed ID: 21748202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal interstitial pneumonitis related to rituximab-containing regimen.
    Herishanu Y; Polliack A; Leider-Trejo L; Grieff Y; Metser U; Naparstek E
    Clin Lymphoma Myeloma; 2006 Mar; 6(5):407-9. PubMed ID: 16640819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
    De Angelis F; Tosti ME; Capria S; Russo E; D'Elia GM; Annechini G; Stefanizzi C; Foà R; Pulsoni A
    Leuk Res; 2015 Dec; 39(12):1382-8. PubMed ID: 26547259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
    Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
    Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy.
    Li C; Lu F; Lei T; Yu H; Chen X; Peng S; Han S; Yang H
    BMC Cancer; 2020 Aug; 20(1):742. PubMed ID: 32770971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine.
    Zimmer P; Mierau A; Bloch W; Strüder HK; Hülsdünker T; Schenk A; Fiebig L; Baumann FT; Hahn M; Reinart N; Hallek M; Elter T
    Leuk Lymphoma; 2015 Feb; 56(2):347-52. PubMed ID: 24738942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
    Balducci L; Mo M; Abella E; Saven A
    Am J Clin Oncol; 2014 Dec; 37(6):603-10. PubMed ID: 25350463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
    Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
    J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.
    Cohen YC; Berger T; Eshel L; Stern D; Bairey O; Raanani P; Shpilberg O
    Isr Med Assoc J; 2017 Jun; 19(6):372-377. PubMed ID: 28647936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
    Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
    J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
    Felli V; Di Sibio A; Anselmi M; Gennarelli A; Sucapane P; Splendiani A; Catalucci A; Marini C; Gallucci M
    Neuroradiol J; 2014 Dec; 27(6):657-64. PubMed ID: 25489887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.